GLP-1 Drugs Cut Addiction Risk and Overdose Deaths Across Six Substances

GLP-1 receptor agonists — the class of drugs behind Ozempic, Wegovy, Mounjaro, and Zepbound — are already reshaping treatment for obesity and type 2 diabetes. Now, the largest study to date on this question suggests they may also be powerful tools against addiction, one of the leading drivers of preventable death and reduced healthspan.

Researchers at Washington University School of Medicine analyzed electronic health records from 606,434 U.S. veterans with type 2 diabetes. Participants were split into those with and without a pre-existing substance use disorder, then followed for up to three years on either a GLP-1 drug or an SGLT2 inhibitor as a comparator. The scale and real-world design give the findings unusual weight.

Among the 524,817 veterans without addiction at baseline, GLP-1 users were 14% less likely to develop a substance use disorder overall. Risk reductions spanned every major substance: opioids (25%), cocaine (20%), nicotine (20%), alcohol (18%), and cannabis (14%). That translated to roughly seven fewer new diagnoses per 1,000 users — a clinically meaningful difference at population scale.

For the 81,617 veterans already living with addiction, GLP-1 use was associated with fewer overdoses, hospitalizations, emergency department visits, and drug-related deaths. The breadth of effect across chemically distinct substances points toward a shared neurobiological mechanism — likely GLP-1 receptor activity in dopamine-driven reward circuits that underlie craving and compulsive use.

Caveats apply. This is an observational study of predominantly male veterans with diabetes, limiting generalizability. Confounding factors cannot be fully excluded. Nonetheless, the findings published in The BMJ represent a major signal. For health-conscious individuals, clinicians, and policymakers, GLP-1 medications are emerging as multi-system interventions with implications far beyond the scale.